Skyscape Web Viewer : The Maudsley Prescribing Guidelines in Psychiatry : Main Index

View All
aspartate aminotransferase (AST) aspirin, valproate interactions psychotropic agent effects
Assessing adherence
A suggested reduction regimen for buprenorphine
asymptomatic neurocognitive impairment (ANI), HIV-related
Ataxia, alcohol effects
Atomoxetine, attention deficit hyperactivity disorder in adults
Atropine Alcohol dependence Clozapine-induced hypersalivation Safer prescribing for physical conditions in dementia
Attachment style of patients affecting relationship with clinician
Attention deficit hyperactivity disorder Attention deficit hyperactivity disorder (ADHD) in children and adolescents medication continuing into adulthood symptoms
Attention deficit hyperactivity disorder (ADHD) drugs in renal impairment
attention deficit hyperactivity disorder (ADHD)
Atypical/typical antipsychotic classification
Atypical eating disorders
Augmentation of treatment
Autism spectrum disorder Autism spectrum disorder (ASD) in children and adolescents Melatonin in the treatment of insomnia in children and adolescents
autism spectrum disorder (ASD) children and adolescents inattention, overactivity and impulsiveness symptoms melatonin use for insomnia pharmacological treatment of co-occurring disorders and problem behaviours pharmacological treatment of core symptoms psychotropic drugs used restricted repetitive behaviours and interests social and communication impairment
Avoid contra-indicated drugs even if not planning pregnancy
Baclofen, preventing relapse after alcohol detoxification
BALANCE study, bipolar disorder Prophylaxis in bipolar disorder Valproate
Bariatric surgery Bariatric surgery drug pharmacokinetic alterations general recommendations for psychotropic prescribing lithium in perioperative phases medication formulation considerations mental health after surgery psychiatric illness risk
Barnes Akathisia Rating Scale
Basic principles of prescribing in depression
Basophils, psychotropic agent effects
behavioural and psychological symptoms of dementia (BPSD) 667-679 non-drug management measures pharmacological measures
Behavioural changes, benzodiazepine-induced disinhibition
Beneficial psychiatric effects, antiseizure medications
benign ethnic neutropenia (BEN) 268 Clozapine, neutropenia and lithium Genetic testing for clozapine treatment
Benperidol
Benzhexol (trihexyphenidyl), clozapine-induced hypersalivation
Benzodiazepine dependence benzodiazepine and cocaine substitution therapy reducing both Benzodiazepine misuse dose reduction recommendations novel illicit drugs overuse of prescribed medication polysubstance use withdrawal management